The ESMO-MCBS is a dynamic tool and one of the main tasks of the ESMO-MCBS Working Group is to maintain the scale and to revise when necessary
The ESMO-MCBS Working Group works in the field of development, research, and education regarding the ESMO-MCBS, a reference tool used by many diverse stakeholders in addressing the issue of value in cancer medicines and treatments.
Activities and Responsibilities
- Maintain and update the scale
- Guarantee continual quality assessment that addresses peer and stakeholder feedback and appeals
- Oversee adherence to highest standards of validity and reasonableness in all ESMO-MCBS processes
- Evaluate and score cancer medicines and treatments approved by regulatory bodies such as the European Medicines Agency
- Provide ESMO-MCBS scores for inclusion in the ESMO Clinical Practice Guidelines
- Update ESMO-MCBS scores when new peer-reviewed evidence becomes available
- Promote clear and unbiased communication about the benefits of cancer treatments
- Knowledge sharing of the tool within the global oncology community
Chair
- Nathan I. Cherny, Israel
Working Group Members
- Jan Bogaerts, Belgium
- Giuseppe Curigliano, Italy
- Urania Dafni, Greece
- Elisabeth G.E. de Vries, Netherlands
- Barbara Kiesewetter, Austria
- Martine J. Piccart, Belgium
- Josep Tabernero, Spain
- Christoph Zielinski, Austria
Extended Working Group Members
- Teresa Amaral, Germany
- Jorge Barriuso, United Kingdom
- Antonio Calles, Spain
- Carlos Gomez-Roca, France
- Bishal Gyawali, Canada
- Sjoukje Oosting, Netherlands
- Antonio Passaro, Italy
- Felipe Roitberg, Brazil
- Noelia Tarazona Llavero, Spain
- Dario Trapani, Italy
- Ruth Wester, Netherlands
- George Zarkavelis, Greece
Last update: September 2020